A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers
- 26 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 87 (6), 779-788
- https://doi.org/10.1007/s00280-021-04235-z
Abstract
Purpose Paclitaxel injection concentrate for nano-dispersion (PICN) is a Cremophor-free, nanotechnology-driven paclitaxel formulation. This phase I study examined the safety, tolerability, pharmacokinetics and maximum tolerated dose (MTD) of PICN alone and in combination with carboplatin. Its early efficacy in unresectable biliary tract cancers (BTCs) was also evaluated. Methods This multi-center study comprised two parts. Part A contained a dose-escalation cohort following “3 + 3” design using PICN monotherapy in advanced solid tumors (Part A1); Part A2 dose-expansion cohort was then conducted in advanced BTCs due to observed efficacy in Part A1. Part B1 and B2 evaluated escalating dose of PICN with carboplatin in advanced solid tumors. PICN was administered as a 30 min-infusion every 3 weeks without pre-medications for hypersensitivity reactions. Results Thirty-six patients received PICN monotherapy in Part A and 21 received PICN plus carboplatin in Part B. The MTD of PICN was determined to be 295 mg/m2 both as a monotherapy and in combination with carboplatin at AUC 5. Dose-proportional exposure in paclitaxel Cmax and AUC was observed overdose range from 175 to 325 mg/m2 for PICN monotherapy and its combination with carboplatin. Carboplatin did not alter PICN exposure. Clinically significant toxicities mainly include neutropenia and peripheral neuropathy. PICN monotherapy yielded a response rate of 20% in unresectable BTCs. Conclusion This study demonstrated the safety and stable pharmacokinetics of PICN as a monotherapy and in combination with carboplatin. Single-agent PICN showed promising antitumor activity in advanced BTCs, warranting further studies to investigate its role in gastrointestinal cancers.Keywords
Funding Information
- Sun Pharma Advanced Research Co. Ltd.
This publication has 22 references indexed in Scilit:
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II TrialJournal of Clinical Oncology, 2011
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in JapanBritish Journal of Cancer, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerThe New England Journal of Medicine, 2010
- Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-PaclitaxelClinical Cancer Research, 2008
- Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatmentJournal of Chromatography B, 2008
- Neoadjuvant Chemotherapy Followed by Aggressive Surgical Consolidation for Metastatic Penile Squamous Cell CarcinomaJournal of Urology, 2007
- Novel formulations of taxanes: a review. Old wine in a new bottle?Annals of Oncology, 2005
- A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinomaCancer, 2000
- THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTSAnnual Review of Medicine, 1997
- Promotion of microtubule assembly in vitro by taxolNature, 1979